Who Owns Sandoz?

• Parent Company: Unknown
• Ownership Type: Wholly owned
• Company Type: State-Owned

• Founded: 1886
• Founders: Edmond Sandoz

• Headquarters: Basel, Switzerland
• Manufacturing / Operations: Switzerland, Germany, Spain, Italy, Austria, United States, India, China

Sandoz operates under comprehensive sustainability and ethics frameworks as an independent global pharmaceutical company. Following its spin-off from Novartis in 2023, Sandoz has established its own environmental, social, and governance (ESG) priorities while maintaining pharmaceutical industry best practices for responsible business operations.

Environmental Sustainability: Sandoz conducted a Double Materiality Assessment (DMA) in 2024 based on the European Sustainability Reporting Standards (ESRS), evaluating ESG issues that affect its business operations and stakeholders. The company has submitted its greenhouse gas reduction targets to the Science Based Targets initiative (SBTi) for validation, demonstrating commitment to climate action aligned with global climate goals.

Patient Access and Affordability: As a leader in generic and biosimilar medicines, Sandoz contributes to healthcare sustainability by providing affordable treatment options. In 2025, the company reported treating 0.9 billion patients with its medicines and reaching an estimated 0.2 billion patients through active pharmaceutical ingredient sales, significantly expanding access to essential medications globally.

Responsible Manufacturing: Sandoz maintains sustainable manufacturing practices across its global production network, focusing on reducing environmental impact while ensuring product quality and safety. The company implements environmental management systems and resource efficiency programs to minimize waste, energy consumption, and water usage in pharmaceutical manufacturing processes.

Ethical Clinical Research: Sandoz maintains strict ethical standards in clinical research and development for generic and biosimilar medicines. The company conducts bioequivalence studies and clinical trials following international guidelines, ensuring patient safety, informed consent, and scientific integrity in all research activities.

Supply Chain Responsibility: Sandoz maintains comprehensive supplier responsibility programs, ensuring ethical sourcing of raw materials and responsible manufacturing practices throughout its pharmaceutical supply chain. The company works with suppliers who meet strict quality, environmental, and social standards for pharmaceutical ingredients and packaging materials.

Corporate Governance: As a publicly traded company on the SIX Swiss Exchange, Sandoz maintains strong corporate governance practices with transparent reporting, stakeholder engagement, and ethical business conduct. The company's independence from Novartis allows focused decision-making on generic and biosimilar business priorities.

Community Engagement: Sandoz engages with healthcare communities globally, supporting initiatives that improve access to medicines, healthcare education, and patient awareness programs. The company's focus on affordable medicines aligns with broader public health goals and sustainable healthcare systems.

Innovation for Sustainability: Sandoz invests in sustainable pharmaceutical innovation, developing more efficient manufacturing processes, reducing environmental footprint of drug production, and creating biosimilar alternatives that reduce healthcare costs while maintaining therapeutic efficacy.

Sandoz has received significant recognition for its successful launch as an independent company and its leadership in the generic and biosimilar pharmaceutical industry. These awards reflect the company's strong market position, innovative approach to affordable medicines, and excellence in corporate communications.

Communique Awards 2024: Sandoz received recognition in the Excellence in Corporate Communications category for "Successfully Launching Sandoz as the Independent Global Leader in Generic and Biosimilar Medicines." This award acknowledged the company's exceptional achievement in establishing itself as a standalone entity following its spin-off from Novartis in 2023, highlighting effective strategic communication during the transition period.

Market Leadership Recognition: Sandoz has been consistently recognized as the global and European number one in generic and biosimilar medicines. The company's position as a market leader has been acknowledged by industry analysts and pharmaceutical publications, particularly for providing approximately 80% of medicines worldwide at just a quarter of the total cost.

Financial Performance Recognition: Sandoz reported strong financial performance in its first independent year, with 9% growth in net sales of generics and biosimilars to third parties for 2024. This growth achievement has been recognized by financial analysts and investment publications as demonstrating successful business strategy execution post-spin-off.

Biosimilar Growth Recognition: The company has received particular recognition for its biosimilar business growth, reporting 29% growth in biosimilar revenues for the first half of 2024. This achievement has been acknowledged by industry organizations like the Center for Biosimilars as demonstrating leadership in the expanding biosimilar market segment.

Industry Leadership Recognition: Sandoz executives and leadership team have been recognized for their contributions to the generic and biosimilar medicines industry. The company's participation in industry associations and thought leadership initiatives has been acknowledged by pharmaceutical trade organizations.

Innovation Recognition: Sandoz has been recognized for innovation in generic and biosimilar development, particularly for its ability to bring complex biosimilar products to market and expand patient access to biologic treatments at more affordable prices.

Patient Access Recognition: The company's focus on treating 0.9 billion patients with its medicines and reaching an estimated 0.2 billion patients through active pharmaceutical ingredient sales has been recognized as a significant contribution to global healthcare access and affordability.

Corporate Governance Recognition: As a newly independent public company, Sandoz has received recognition for establishing strong corporate governance practices and transparent reporting standards, particularly for its comprehensive ESG reporting and sustainability initiatives.

Sandoz has maintained a relatively clean operational record as an independent company, though it has faced some product recalls and regulatory challenges typical of the pharmaceutical industry. The company's focus on generic and biosimilar medicines has resulted in fewer controversies compared to innovative pharmaceutical companies with novel drug development risks.

Cefazolin Injection Recall (2025): In July 2025, Sandoz Inc. issued a voluntary nationwide recall of several lots of Cefazolin for Injection, USP, 1 gram per vial, due to product mispackaging issues. The recall was initiated after customer complaints indicated that some vials were incorrectly labeled as Penicillin G Potassium for Injection, USP. The FDA announced the recall on July 14, 2025, though Sandoz reported that it had not received any adverse events related to the mispackaging issue. The recalled products were distributed nationwide to wholesalers and distributors between December 4, 2024 and May 15, 2025.

Regulatory Compliance Challenges: As a global pharmaceutical manufacturer operating in multiple markets, Sandoz faces ongoing regulatory compliance challenges across different jurisdictions. The company must maintain compliance with varying regulatory requirements for generic drug approval, biosimilar development, and pharmaceutical manufacturing standards across the United States, Europe, Asia, and other markets where it operates.

Biosimilar Development Complexities: Sandoz's expansion into biosimilar medicines presents inherent challenges related to demonstrating bioequivalence, navigating complex regulatory pathways, and addressing intellectual property issues. The company faces competition from both original biologic manufacturers and other biosimilar developers, creating a competitive landscape that requires continuous innovation and strategic positioning.

Generic Drug Competition: The generic pharmaceutical market is highly competitive, with price pressure from other generic manufacturers and increasing consolidation in the industry. Sandoz must balance affordability with profitability while maintaining quality standards and regulatory compliance across its extensive product portfolio.

Supply Chain Quality Control: Like all pharmaceutical manufacturers, Sandoz faces ongoing challenges related to maintaining quality control across its global supply chain. The company must ensure consistent product quality across multiple manufacturing facilities while managing complex logistics for temperature-sensitive pharmaceutical products.

Patent Litigation and Intellectual Property: Sandoz operates in an environment where patent litigation is common in the pharmaceutical industry. The company must carefully navigate patent expiration timelines and intellectual property rights when developing generic and biosimilar products, potentially facing legal challenges from brand-name pharmaceutical manufacturers.

Pricing and Market Access Pressures: As a provider of affordable medicines, Sandoz faces ongoing pressure from healthcare systems and payers regarding pricing and market access. The company must balance its business objectives with broader healthcare affordability goals while maintaining sustainable operations and investment in research and development.

Current Status: Sandoz continues to operate successfully as an independent company, maintaining its position as a global leader in generic and biosimilar medicines. The company's strong financial performance and market position following its spin-off from Novartis demonstrate effective business strategy execution and operational excellence in the competitive pharmaceutical landscape.